Pacific Biosciences of California, Inc. (PACB) Debt Components
- 2024-12-31: Short-term DebtUSD $0.00; Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m).
- 2023-12-31: Short-term DebtUSD $490.00K; Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m).
- 2023-12-31: Short-term DebtUSD (m); Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m).
- 2023-03-31: Short-term DebtUSD (m); Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m).
Pacific Biosciences of California, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Short-term Debt USD | Notes Payable, Current USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Notes Payable USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Fair Value Disclosure USD | Long-term Debt, Fair Value USD | Debt Instrument, Unamortized Discount USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $490.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | $500.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $896.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.16M |
| 2022-12-31 | $1.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $896.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.32M |
| 2022-12-31 | (m) | $1.80M | (m) | (m) | $2.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | $896.53M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00M | (m) | (m) | (m) | (m) | $3.47M |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | $896.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00M | (m) | (m) | (m) | (m) | $3.63M |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | $896.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00M | (m) | (m) | (m) | (m) | $3.78M |
| 2021-12-31 | $1.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | $896.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00M | (m) | (m) | (m) | (m) | $3.93M |
| 2021-12-31 | (m) | $1.60M | (m) | (m) | $3.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | $895.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00M | (m) | (m) | (m) | (m) | $4.08M |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | $895.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00M | (m) | (m) | (m) | (m) | $4.24M |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $895.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00M | (m) | (m) | (m) | (m) | $4.33M |
| 2019-12-31 | (m) | $16.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $15.87M | $16.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $15.55M | (m) | (m) | (m) | $15.55M | (m) | $16.49M | (m) | (m) | (m) | (m) | $353.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $15.23M | (m) | (m) | (m) | $15.23M | (m) | $16.49M | (m) | (m) | (m) | (m) | $702.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $14.94M | (m) | (m) | (m) | $14.94M | (m) | $16.49M | (m) | (m) | (m) | (m) | $1.05M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $14.66M | $1.40M | $16.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $14.38M | $353.00K | $1.40M | $16.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $14.12M | $702.00K | $1.40M | $16.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $13.87M | $1.05M | $1.40M | $16.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $13.63M | $1.40M | $1.40M | $16.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $2.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $2.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $3.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $16.11M | $1.79M | $5.38M | $2.82M | $15.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $1.80M | $1.79M | $5.63M | $2.82M | $15.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | $14.12M | $1.79M | $1.80M | $1.79M | $5.63M | (m) | $17.96M | $28.98M | (m) | (m) | (m) | (m) | $6.40M | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.13M | (m) | $6.60M | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.13M | (m) | $6.80M | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $14.55M | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $14.55M | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | $13.35M | (m) | $13.35M | $1.79M | $1.79M | $1.80M | $1.79M | (m) | $23.59M | $30.77M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $13.69M | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $182.00K | $2.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-02-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $20.50M | (m) | (m) | (m) | (m) |
| 2013-02-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $12.80M | (m) | (m) | $14.10M | $7.70M | (m) |
| 2013-02-05 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $14.10M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $173.00K | $2.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $165.00K | $2.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $156.00K | $2.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $148.00K | $2.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $140.00K | $2.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | $132.00K | $2.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $125.00K | $2.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $110.00K | $2.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |